GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study-Reference-Cited by-同舟云学术

GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study

Published:2007-11-15 Issue:2 Volume:80 Page:127-132
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:

Author:

López Andrés,Gutiérrez Antonio,Palacios Andrés,Blancas Isabel,Navarrete Maite,Morey Miguel,Perelló Antonia,Alarcón Jesús,Martínez Jordi,Rodríguez José

Publisher

Wiley

Subject

Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0609.2007.00996.x/fullpdf

Reference25 articles.

1. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma;Philip;N Engl J Med,1995

2. EPIC: an effective low toxicity regimen for relapsing lymphoma;Hickish;Br J Cancer,1993

3. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin’s lymphoma patients;Germann;Ann Oncol,1999

4. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP);Velasquez;Blood,1988

5. ESHAP - an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study;Velasquez;J Clin Oncol,1994

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group;Clinical Cancer Research;2024-06-20

2. Sintilimab plus GemOx is an effective salvage therapy in patients with refractory⁄relapsing nodal peripheral T cell lymphomas;2024-03-28

3. Second Line Treatment of DLBCL: Evolution of Options;Seminars in Hematology;2023-12

4. Cost‐effectiveness analysis of transplant‐ineligible relapsed or refractory diffuse large B‐cell lymphoma treatment options—Experience of the efficiency frontier approach;European Journal of Haematology;2023-08-29

5. What to Do When Chimeric Antigen Receptor T Cells Are Not the Most Appropriate Option in Second-Line Diffuse Large B Cell Lymphoma: Current Treatment Options for Transplant-Ineligible Patients;EMJ Hematology;2023-08-01